|
| 36399499 | The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. | Nucleic Acids Res | 2023 |
| 37066232 | Towards robust clinical genome interpretation: developing a consistent terminology to characterize disease-gene relationships - allelic requirement, inheritance modes and disease mechanisms. | medRxiv | 2023 |
| 36477213 | EMBL's European Bioinformatics Institute (EMBL-EBI) in 2022. | Nucleic Acids Res | 2023 |
| 35507016 | The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. | Genet Med | 2022 |
| 35804044 | Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. | Nat Rev Drug Discov | 2022 |
| 33045747 | Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. | Nucleic Acids Res | 2021 |
| 34758253 | 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. | N Engl J Med | 2021 |
| 34402426 | A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance. | Elife | 2021 |
| 34329581 | Scaling national and international improvement in virtual gene panel curation via a collaborative approach to discordance resolution. | Am J Hum Genet | 2021 |
| 33196847 | Open Targets Platform: supporting systematic drug-target identification and prioritisation. | Nucleic Acids Res | 2021 |
| 33245775 | The European Bioinformatics Institute: empowering cooperation in response to a global health crisis. | Nucleic Acids Res | 2021 |
| 30406943 | Essential Characteristics of Pharmacogenomics Study Publications. | Clin Pharmacol Ther | 2019 |
| 31676867 | PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. | Nat Genet | 2019 |
| 29691228 | The 100â¿¿000 Genomes Project: bringing whole genome sequencing to the NHS. | BMJ | 2018 |
| 27636560 | PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. | Pharmacogenet Genomics | 2017 |
| 28271586 | Single-base substitutions in the CHM promoter as a cause of choroideremia. | Hum Mutat | 2017 |
| 26094938 | Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. | Clin Pharmacol Ther | 2016 |
| 27232112 | PharmGKB summary: isoniazid pathway, pharmacokinetics. | Pharmacogenet Genomics | 2016 |
| 25514096 | PharmGKB summary: very important pharmacogene information for CFTR. | Pharmacogenet Genomics | 2015 |
| 26398623 | PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics. | Pharmacogenet Genomics | 2015 |
| 25966836 | PharmGKB summary: Efavirenz pathway, pharmacokinetics. | Pharmacogenet Genomics | 2015 |
| 25670512 | Enabling the curation of your pharmacogenetic study. | Clin Pharmacol Ther | 2015 |
| 24479687 | Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. | Curr Drug Metab | 2014 |
| 24787449 | Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. | Clin Pharmacol Ther | 2014 |
| 24892773 | PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. | Pharmacogenet Genomics | 2014 |
| 24915143 | PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. | Pharmacogenet Genomics | 2014 |
| 24598717 | Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. | Clin Pharmacol Ther | 2014 |
| 23407052 | Nomenclature for alleles of the thiopurine methyltransferase gene. | Pharmacogenet Genomics | 2013 |
| 23913015 | PharmGKB summary: methylene blue pathway. | Pharmacogenet Genomics | 2013 |
| 22293536 | PharmGKB summary: caffeine pathway. | Pharmacogenet Genomics | 2012 |
| 22992668 | Pharmacogenomics knowledge for personalized medicine. | Clin Pharmacol Ther | 2012 |
| 22547082 | PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | Pharmacogenet Genomics | 2012 |
| 22237549 | PharmGKB summary: very important pharmacogene information for G6PD. | Pharmacogenet Genomics | 2012 |
| 22103613 | From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. | Biomark Med | 2011 |
| 18174362 | CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. | J Leukoc Biol | 2008 |
| 18453591 | The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. | J Immunol | 2008 |